Cargando…

Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy

OBJECTIVE: This study compared the effect of levetiracetam (LEV) as monotherapy to sodium valproate (VPA) as monotherapy on cognitive functions in patients with epilepsy. METHODS: This was a comparative prospective study on 50 patients with newly diagnosed epilepsy started on antiseizure medications...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sabaa, Ramy M, Hamdi, Emad, Hamdy, Nermin Aly, Sarhan, Hatem A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429224/
https://www.ncbi.nlm.nih.gov/pubmed/32848400
http://dx.doi.org/10.2147/NDT.S256117
_version_ 1783571245835485184
author El Sabaa, Ramy M
Hamdi, Emad
Hamdy, Nermin Aly
Sarhan, Hatem A
author_facet El Sabaa, Ramy M
Hamdi, Emad
Hamdy, Nermin Aly
Sarhan, Hatem A
author_sort El Sabaa, Ramy M
collection PubMed
description OBJECTIVE: This study compared the effect of levetiracetam (LEV) as monotherapy to sodium valproate (VPA) as monotherapy on cognitive functions in patients with epilepsy. METHODS: This was a comparative prospective study on 50 patients with newly diagnosed epilepsy started on antiseizure medications. Patients were selected from the neurology-outpatient clinics at Minia University Hospital, Minia, Egypt. They were divided into two groups: group treated with LEV and group treated with VPA. All patients were subjected to cognitive function assessment using reaction-time tests, trail-making tests, and Wisconsin card-sorting test before treatment and 3 months after treatment. RESULTS: Both groups of patients showed reduction in seizure frequency. However, patients on LEV showed significant improvement in measured cognitive functions 3 months after starting treatment, while patients in the VPA group showed significant impairment in measured cognitive functions 3 months after starting treatment. CONCLUSION: Both groups of patients showed reduction in seizure frequency. However, patients on LEV showed significant improvement in measured cognitive functions 3 months after starting treatment, while patients in the VPA group showed significant impairment in measured cognitive functions 3 months after starting treatment.
format Online
Article
Text
id pubmed-7429224
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74292242020-08-25 Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy El Sabaa, Ramy M Hamdi, Emad Hamdy, Nermin Aly Sarhan, Hatem A Neuropsychiatr Dis Treat Original Research OBJECTIVE: This study compared the effect of levetiracetam (LEV) as monotherapy to sodium valproate (VPA) as monotherapy on cognitive functions in patients with epilepsy. METHODS: This was a comparative prospective study on 50 patients with newly diagnosed epilepsy started on antiseizure medications. Patients were selected from the neurology-outpatient clinics at Minia University Hospital, Minia, Egypt. They were divided into two groups: group treated with LEV and group treated with VPA. All patients were subjected to cognitive function assessment using reaction-time tests, trail-making tests, and Wisconsin card-sorting test before treatment and 3 months after treatment. RESULTS: Both groups of patients showed reduction in seizure frequency. However, patients on LEV showed significant improvement in measured cognitive functions 3 months after starting treatment, while patients in the VPA group showed significant impairment in measured cognitive functions 3 months after starting treatment. CONCLUSION: Both groups of patients showed reduction in seizure frequency. However, patients on LEV showed significant improvement in measured cognitive functions 3 months after starting treatment, while patients in the VPA group showed significant impairment in measured cognitive functions 3 months after starting treatment. Dove 2020-08-11 /pmc/articles/PMC7429224/ /pubmed/32848400 http://dx.doi.org/10.2147/NDT.S256117 Text en © 2020 El Sabaa et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
El Sabaa, Ramy M
Hamdi, Emad
Hamdy, Nermin Aly
Sarhan, Hatem A
Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy
title Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy
title_full Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy
title_fullStr Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy
title_full_unstemmed Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy
title_short Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy
title_sort effects of levetiracetam compared to valproate on cognitive functions of patients with epilepsy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429224/
https://www.ncbi.nlm.nih.gov/pubmed/32848400
http://dx.doi.org/10.2147/NDT.S256117
work_keys_str_mv AT elsabaaramym effectsoflevetiracetamcomparedtovalproateoncognitivefunctionsofpatientswithepilepsy
AT hamdiemad effectsoflevetiracetamcomparedtovalproateoncognitivefunctionsofpatientswithepilepsy
AT hamdynerminaly effectsoflevetiracetamcomparedtovalproateoncognitivefunctionsofpatientswithepilepsy
AT sarhanhatema effectsoflevetiracetamcomparedtovalproateoncognitivefunctionsofpatientswithepilepsy